Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cash-Tight MAP Could Win With Inhaled Migraine Drug

This article was originally published in The Pink Sheet Daily

Executive Summary

Merck’s switch to backup CGRP after liver-enzyme trouble could provide an edge to MAP Pharmaceuticals.

You may also be interested in...

Merck Delays Migraine Drug Filing; Q1 Sales Fall Short of Analyst Expectations

Telcagepant approval, next anticipated opportunity in pipeline, at standstill; analysts look to Schering-Plough deal to bolster Merck sales.

NDA Submitted, MannKind’s Inhaled Insulin Faces Next Test: Finding A Partner

Deal terms may show pharma’s faith that Afresa can beat the stigma of Pfizer’s fizzled Exubera.

Another Hybrid License Deal: Chiesi Buys Majority Stake In Cornerstone

In a creative deal that echoes the strategic tie-up last year between Infinity and Mundipharma, Italian giant Chiesi Farmaceutici is buying a majority stake in Cornerstone Therapeutics, which gets $15.5 million along with U.S. rights for 10 years to Chiesi's marketed lung surfactant Curosurf





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts